[
    {
        "id": 5712,
        "drug_name": "DOVATO (Dolutegravir + lamivudine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-06",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200806006103\/en\/",
        "note": "FDA approval announced August 6, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3821,
        "drug_name": "OLINVYK (oliceridine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Moderate to severe acute pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-07",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-new-opioid-for-intravenous-use-in-hospitals-other-controlled-clinical-settings-301108621.html",
        "note": "FDA Approval announced August 7, 2020.",
        "company_entity_id": 296,
        "company_ticker": "TRVN",
        "company_name": "Trevena Inc.",
        "company_price": "0.5622",
        "company_change": 0,
        "company_percent_change": -0.5,
        "company_optionable": 1,
        "company_number_of_shares": 18321101,
        "price_change_sparkline": [
            [
                0.6409,
                1706677200
            ],
            [
                0.624,
                1706763600
            ],
            [
                0.6179,
                1706850000
            ],
            [
                0.5762,
                1707109200
            ],
            [
                0.5815,
                1707195600
            ],
            [
                0.5974,
                1707282000
            ],
            [
                0.5703,
                1707368400
            ],
            [
                0.5855,
                1707454800
            ],
            [
                0.58,
                1707714000
            ],
            [
                0.58,
                1707800400
            ],
            [
                0.6068,
                1707886800
            ],
            [
                0.6195,
                1707973200
            ],
            [
                0.571,
                1708059600
            ],
            [
                0.5692,
                1708405200
            ],
            [
                0.5656,
                1708491600
            ],
            [
                0.5682,
                1708578000
            ],
            [
                0.5611,
                1708664400
            ],
            [
                0.5775,
                1708923600
            ],
            [
                0.581,
                1709010000
            ],
            [
                0.57,
                1709096400
            ],
            [
                0.581,
                1709182800
            ],
            [
                0.5709,
                1709269200
            ],
            [
                0.5899,
                1709528400
            ],
            [
                0.5654,
                1709614800
            ],
            [
                0.5799,
                1709701200
            ],
            [
                0.558,
                1709787600
            ],
            [
                0.5743,
                1709874000
            ],
            [
                0.565,
                1710129600
            ],
            [
                0.5687,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4580,
        "drug_name": "EVRYSDI (risdiplam)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Spinal Muscular Atrophy (SMA) Type 1",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-07",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200807005410\/en\/",
        "note": "FDA Approval announced August 7, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4580,
        "drug_name": "EVRYSDI (risdiplam)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Spinal Muscular Atrophy (SMA) Type 1",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-07",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200807005410\/en\/",
        "note": "FDA Approval announced August 7, 2020.",
        "company_entity_id": 251,
        "company_ticker": "PTCT",
        "company_name": "PTC Therapeutics Inc.",
        "company_price": "31.6900",
        "company_change": 0.99,
        "company_percent_change": 3.22,
        "company_optionable": 1,
        "company_number_of_shares": 76608030,
        "price_change_sparkline": [
            [
                26.09,
                1706677200
            ],
            [
                26.03,
                1706763600
            ],
            [
                25.18,
                1706850000
            ],
            [
                25.07,
                1707109200
            ],
            [
                26.79,
                1707195600
            ],
            [
                25.24,
                1707282000
            ],
            [
                25.25,
                1707368400
            ],
            [
                25.51,
                1707454800
            ],
            [
                25.92,
                1707714000
            ],
            [
                24.15,
                1707800400
            ],
            [
                25.04,
                1707886800
            ],
            [
                25.69,
                1707973200
            ],
            [
                25.91,
                1708059600
            ],
            [
                25.98,
                1708405200
            ],
            [
                25.94,
                1708491600
            ],
            [
                26.04,
                1708578000
            ],
            [
                27.07,
                1708664400
            ],
            [
                27.95,
                1708923600
            ],
            [
                28.31,
                1709010000
            ],
            [
                28.2,
                1709096400
            ],
            [
                28.19,
                1709182800
            ],
            [
                31.95,
                1709269200
            ],
            [
                30.98,
                1709528400
            ],
            [
                31.3,
                1709614800
            ],
            [
                30.88,
                1709701200
            ],
            [
                30.76,
                1709787600
            ],
            [
                31.16,
                1709874000
            ],
            [
                30.7,
                1710129600
            ],
            [
                31.69,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6061,
        "drug_name": "ENSPRYNG (satralizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neuromyelitis optica spectrum disorder (NMOSD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-14",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200814005501\/en\/",
        "note": "FDA approval announced August 14, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6750,
        "drug_name": "Dimethyl fumarate (generic)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple sclerosis - Tecfidera generic",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-17",
        "link": "https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1623613\/000162361320000035\/myl-20200930.htm",
        "note": "FDA approved August 17, 2020.",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2825,
        "drug_name": "ARZERRA (ofatumumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsing multiple sclerosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-20",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/7ef8a458-fbb2-4244-a09f-79d1de9fb67b",
        "note": "FDA approval announced August 20, 2020.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2825,
        "drug_name": "ARZERRA (ofatumumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsing multiple sclerosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-20",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/7ef8a458-fbb2-4244-a09f-79d1de9fb67b",
        "note": "FDA approval announced August 20, 2020.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5444,
        "drug_name": "DARZALEX (Daratumumab) and KYPROLIS (carfilzomib)",
        "clinical_trial_id": "NCT03158688",
        "has_trial_insight_page": 0,
        "indication": "Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-20",
        "link": "https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-janssen-granted-us-fda-approval-darzalexr",
        "note": "FDA approval announced August 20, 2020.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5444,
        "drug_name": "DARZALEX (Daratumumab) and KYPROLIS (carfilzomib)",
        "clinical_trial_id": "NCT03158688",
        "has_trial_insight_page": 0,
        "indication": "Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-20",
        "link": "https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-janssen-granted-us-fda-approval-darzalexr",
        "note": "FDA approval announced August 20, 2020.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2927,
        "drug_name": "CC-486-AML-001",
        "clinical_trial_id": "NCT01757535",
        "has_trial_insight_page": 0,
        "indication": "AML Maintenance",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200901005914\/en\/",
        "note": "FDA approval announced September 1, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5976,
        "drug_name": "GAVRETO (Pralsetinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "RET-fusion non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-04",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/09\/n17393251\/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adults-with",
        "note": "FDA Approval announced September 4, 2020.",
        "company_entity_id": 439,
        "company_ticker": "BPMC",
        "company_name": "Blueprint Medicines Corporation",
        "company_price": "89.7000",
        "company_change": 0.23,
        "company_percent_change": 0.26,
        "company_optionable": 1,
        "company_number_of_shares": 61232297,
        "price_change_sparkline": [
            [
                79.53,
                1706677200
            ],
            [
                79.88,
                1706763600
            ],
            [
                79.58,
                1706850000
            ],
            [
                76.66,
                1707109200
            ],
            [
                77.17,
                1707195600
            ],
            [
                74.2,
                1707282000
            ],
            [
                74.16,
                1707368400
            ],
            [
                76.54,
                1707454800
            ],
            [
                77.54,
                1707714000
            ],
            [
                73.17,
                1707800400
            ],
            [
                76.8,
                1707886800
            ],
            [
                87.57,
                1707973200
            ],
            [
                90.26,
                1708059600
            ],
            [
                91.25,
                1708405200
            ],
            [
                87.26,
                1708491600
            ],
            [
                86,
                1708578000
            ],
            [
                89.49,
                1708664400
            ],
            [
                95.05,
                1708923600
            ],
            [
                99.79,
                1709010000
            ],
            [
                95.45,
                1709096400
            ],
            [
                93.52,
                1709182800
            ],
            [
                95.12,
                1709269200
            ],
            [
                90.8,
                1709528400
            ],
            [
                89.67,
                1709614800
            ],
            [
                90.38,
                1709701200
            ],
            [
                92.04,
                1709787600
            ],
            [
                92.3,
                1709874000
            ],
            [
                89.47,
                1710129600
            ],
            [
                89.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3068,
        "drug_name": "TRELEGY ELLIPTA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Asthma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-09",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200909006117\/en\/",
        "note": "FDA approval announced September 9, 2020.",
        "company_entity_id": 289,
        "company_ticker": "TBPH",
        "company_name": "Theravance Biopharma Inc.",
        "company_price": "8.5200",
        "company_change": -0.050000000000000044,
        "company_percent_change": -0.5800000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 48164708,
        "price_change_sparkline": [
            [
                9.48,
                1706677200
            ],
            [
                9.16,
                1706763600
            ],
            [
                8.9,
                1706850000
            ],
            [
                8.85,
                1707109200
            ],
            [
                8.82,
                1707195600
            ],
            [
                8.5,
                1707282000
            ],
            [
                8.22,
                1707368400
            ],
            [
                8.58,
                1707454800
            ],
            [
                8.58,
                1707714000
            ],
            [
                8.35,
                1707800400
            ],
            [
                8.46,
                1707886800
            ],
            [
                8.67,
                1707973200
            ],
            [
                8.8,
                1708059600
            ],
            [
                8.92,
                1708405200
            ],
            [
                8.76,
                1708491600
            ],
            [
                8.675,
                1708578000
            ],
            [
                8.98,
                1708664400
            ],
            [
                9.23,
                1708923600
            ],
            [
                9.69,
                1709010000
            ],
            [
                9.4,
                1709096400
            ],
            [
                9.47,
                1709182800
            ],
            [
                9.44,
                1709269200
            ],
            [
                9.1,
                1709528400
            ],
            [
                8.67,
                1709614800
            ],
            [
                8.74,
                1709701200
            ],
            [
                8.69,
                1709787600
            ],
            [
                8.62,
                1709874000
            ],
            [
                8.57,
                1710129600
            ],
            [
                8.52,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3068,
        "drug_name": "TRELEGY ELLIPTA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Asthma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-09",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200909006117\/en\/",
        "note": "FDA approval announced September 9, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3068,
        "drug_name": "TRELEGY ELLIPTA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Asthma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-09",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200909006117\/en\/",
        "note": "FDA approval announced September 9, 2020.",
        "company_entity_id": 391,
        "company_ticker": "INVA",
        "company_name": "Innoviva Inc.",
        "company_price": "14.8200",
        "company_change": 0.03,
        "company_percent_change": 0.2,
        "company_optionable": 1,
        "company_number_of_shares": 63227333,
        "price_change_sparkline": [
            [
                16.2,
                1706677200
            ],
            [
                16.29,
                1706763600
            ],
            [
                15.9,
                1706850000
            ],
            [
                15.82,
                1707109200
            ],
            [
                15.89,
                1707195600
            ],
            [
                15.53,
                1707282000
            ],
            [
                15.6,
                1707368400
            ],
            [
                15.69,
                1707454800
            ],
            [
                15.71,
                1707714000
            ],
            [
                15.48,
                1707800400
            ],
            [
                15.8,
                1707886800
            ],
            [
                16,
                1707973200
            ],
            [
                15.86,
                1708059600
            ],
            [
                15.8,
                1708405200
            ],
            [
                15.67,
                1708491600
            ],
            [
                15.48,
                1708578000
            ],
            [
                15.48,
                1708664400
            ],
            [
                15.52,
                1708923600
            ],
            [
                15.37,
                1709010000
            ],
            [
                15.35,
                1709096400
            ],
            [
                15.28,
                1709182800
            ],
            [
                15.24,
                1709269200
            ],
            [
                15.26,
                1709528400
            ],
            [
                14.88,
                1709614800
            ],
            [
                15.18,
                1709701200
            ],
            [
                15.08,
                1709787600
            ],
            [
                14.84,
                1709874000
            ],
            [
                14.79,
                1710129600
            ],
            [
                14.82,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2577,
        "drug_name": "NUCALA (Mepolizumab)",
        "clinical_trial_id": "NCT02836496",
        "has_trial_insight_page": 0,
        "indication": "Severe hypereosinophilic syndrome (HES)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-25",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200925005503\/en\/",
        "note": "FDA approval announced September 25, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5252,
        "drug_name": "Novothyrox (EM-100)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Allergic conjunctivitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-25",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-bausch--lomb-alaway-preservative-free-ketotifen-fumarate-ophthalmic-solution-0-035-301138158.html",
        "note": "FDA approval announced September 25, 2020.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5252,
        "drug_name": "Novothyrox (EM-100)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Allergic conjunctivitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-25",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-bausch--lomb-alaway-preservative-free-ketotifen-fumarate-ophthalmic-solution-0-035-301138158.html",
        "note": "FDA approval announced September 25, 2020.",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6848,
        "drug_name": "Alkindi Sprinkle",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pediatric adrenal insufficiency (AI) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-09-29",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/09\/g17708567\/eton-pharmaceuticals-announces-fda-approval-of-orphan-drug-alkindi-sprinkle-hydrocortisone-as-repl",
        "note": "FDA approval announced September 29, 2020.",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5433,
        "drug_name": "OPDIVO (nivolumab) + YERVOY (ipilimumab)",
        "clinical_trial_id": "NCT02899299",
        "has_trial_insight_page": 0,
        "indication": "Mesothelioma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-02",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201002005481\/en\/",
        "note": "FDA approval announced October 2, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6972,
        "drug_name": "WAKIX (pitolisant)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Adult cataplexy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-14",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/harmony-biosciences-receives-fda-approval-for-expanded-use-of-wakix-pitolisant-for-the-treatment-of-cataplexy-in-adult-patients-with-narcolepsy-301152078.html",
        "note": "FDA approval announced October 14, 2020.",
        "company_entity_id": 804,
        "company_ticker": "HRMY",
        "company_name": "Harmony Biosciences Holdings Inc.",
        "company_price": "30.4200",
        "company_change": -0.36,
        "company_percent_change": -1.17,
        "company_optionable": 1,
        "company_number_of_shares": 56769081,
        "price_change_sparkline": [
            [
                31.54,
                1706677200
            ],
            [
                31.29,
                1706763600
            ],
            [
                31.17,
                1706850000
            ],
            [
                30.32,
                1707109200
            ],
            [
                31.52,
                1707195600
            ],
            [
                31.89,
                1707282000
            ],
            [
                33.7,
                1707368400
            ],
            [
                33.31,
                1707454800
            ],
            [
                34.56,
                1707714000
            ],
            [
                32.87,
                1707800400
            ],
            [
                33.89,
                1707886800
            ],
            [
                35.06,
                1707973200
            ],
            [
                33.81,
                1708059600
            ],
            [
                33.02,
                1708405200
            ],
            [
                33,
                1708491600
            ],
            [
                31.45,
                1708578000
            ],
            [
                32.5,
                1708664400
            ],
            [
                32.47,
                1708923600
            ],
            [
                33.48,
                1709010000
            ],
            [
                33.26,
                1709096400
            ],
            [
                32.1,
                1709182800
            ],
            [
                32.11,
                1709269200
            ],
            [
                30.87,
                1709528400
            ],
            [
                30.75,
                1709614800
            ],
            [
                30.68,
                1709701200
            ],
            [
                31.04,
                1709787600
            ],
            [
                31.09,
                1709874000
            ],
            [
                30.78,
                1710129600
            ],
            [
                30.42,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6392,
        "drug_name": "INMAZEB (atoltivimab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ebola",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-14",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus",
        "note": "FDA Approval announced October 14, 2020.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6460,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "NCT02684292",
        "has_trial_insight_page": 0,
        "indication": "Classical Hodgkin lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201015005355\/en\/",
        "note": "FDA Approval announced October 15, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6400,
        "drug_name": "VENCLEXTA (venetoclax) - (VIALE-A)",
        "clinical_trial_id": "NCT02993523",
        "has_trial_insight_page": 0,
        "indication": "Acute Myeloid Leukemia (AML)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-16",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/venclexta-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml-301154267.html",
        "note": "FDA approval announced October 16, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    }
]